Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis

“Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis…The endocannabinoid system and cannabimimetic compounds protect against effects of allergic inflammatory disorders in various species of mammals. Results of the present study contributed to knowledge of the endocannabinoid system and indicated this system may be a target for treatment of immune-mediated and inflammatory disorders such as allergic skin diseases in dogs.”

http://www.ncbi.nlm.nih.gov/pubmed/22738050

The effects of hempseed meal intake and linoleic acid on Drosophila models of neurodegenerative diseases and hypercholesterolemia

Molecules and Cells

“Hemp seed is rich in polyunsaturated fatty acids (PUFAs), which have potential as therapeutic compounds for the treatment of neurodegenerative and cardiovascular disease.

In this study, we assessed the effects of the intake of  hempseed meal (HSM) and PUFAs on oxidative stress, cytotoxicity and neurological phenotypes, and cholesterol uptake, using Drosophila models.

HSM intake was shown to reduce H(2)O(2) toxicity markedly, indicating that HSM exerts a profound antioxidant effect.

Meanwhile, intake of HSM, as well as linoleic or linolenic acids (major PUFA components of HSM) was shown to ameliorate Aβ42-induced eye degeneration, thus suggesting that these compounds exert a protective effect against Aβ42 cytotoxicity.

Additionally, intake of HSM or linoleic acid was shown to reduce cholesterol uptake significantly.

Moreover, linoleic acid intake has been shown to delay pupariation, and cholesterol feeding rescued the linoleic acid-induced larval growth delay, thereby indicating that linoleic acid acts antagonistically with cholesterol during larval growth.

In conclusion, our results indicate that HSM and linoleic acid exert inhibitory effects on both Aβ42 cytotoxicity and cholesterol uptake, and are potential candidates for the treatment of Alzheimer’s disease and cardiovascular disease.”

http://www.ncbi.nlm.nih.gov/pubmed/21331775 

“A number of previous studies have shown that polyunsaturated fatty acids (PUFAs) and phytosterols are critically important for human health. Hempseed is a rich source of plant oil, which contains more than 80% PUFAs and 3922-6719 mg/kg of phytosterols (e.g., sitosterol and campesterol). The fatty acids in hempseed oil include a variety of essential fatty acids, including linoleic acid ”

https://link.springer.com/article/10.1007%2Fs10059-011-0042-6

7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists

“Cannabinoid receptor agonists have gained attention as potential therapeutic targets of inflammatory and neuropathic pain. Here, we report the identification and optimization of a series of 7-oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide derivatives as a novel chemotype of selective cannabinoid CB2 receptor agonists… 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists.”

http://www.ncbi.nlm.nih.gov/pubmed/22738271

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress

“Cannabidiol (CBD) is the most abundant cannabinoid in Cannabis sativa that has no psychoactive properties. CBD has been approved to treat inflammation, pain and spasticity associated with multiple sclerosis (MS), of which demyelination and oligodendrocyte loss are hallmarks. Thus, we investigated the protective effects of CBD against the damage to oligodendrocyte progenitor cells (OPCs) mediated by the immune system… Cannabidiol protects oligodendrocyte progenitor cells… These findings suggest that attenuation of the ER stress pathway is involved in the ‘oligoprotective’ effects of CBD during inflammation.”

http://www.ncbi.nlm.nih.gov/pubmed/22739983

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon

“Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions…” and “Cannabinoid receptor activation induces apoptosis… in colon cancer cells”

http://www.ncbi.nlm.nih.gov/pubmed/19479993

Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury

“Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury… These results demonstrate that the improvement in motor and autonomic function resulting from treatment with a selective CB2 agonist is associated with a significant effect on inflammatory responses in the spinal cord following injury.”

http://www.ncbi.nlm.nih.gov/pubmed/21970496

Cannabinoids for gastrointestinal diseases: potential therapeutic applications

“…pharmacological modulation of the endogenous cannabinoid system could provide new therapeutics for the treatment of a number of gastrointestinal diseases, including nausea and vomiting, gastric ulcers, irritable bowel syndrome, Crohn’s disease, secretory diarrhoea, paralytic ileus and gastroesophageal reflux disease. Some cannabinoids are already in use…”

http://www.ncbi.nlm.nih.gov/pubmed/12517253

Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases

“Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases… Many beneficial effects of herbal cannabinoids on gut motility and inflammation have been demonstrated, suggesting a vast potential for these compounds in the treatment of gastrointestinal disorders….endocannabinoid system’ (ECS), a cooperating network of molecules that regulate themetabolism of the body’s own and of exogenously administered cannabinoids. The ECS… offering many potential targets for pharmacological intervention. Of major therapeutic interest are nonpsychoactive cannabinoids that do not directly target cannabinoid receptors but still possess cannabinoid-like properties… promising alternative therapeutic tools to manipulate the ECS.”

http://www.ncbi.nlm.nih.gov/pubmed/21876860

Normal Human Pituitary Gland and Pituitary Adenomas Express Cannabinoid Receptor Type 1 and Synthesize Endogenous Cannabinoids

“…we report for the first time the expression of CB1 in the human pituitary gland and human pituitary adenomas… cannabinoid-induced modulation of hormonal release were shown… these results indicate a potentially important role of the endocannabinoid system in pituitary pathophysiology, thus opening new perspectives in the management of pituitary adenomas… The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion.”

http://jcem.endojournals.org/content/86/6/2687.long

Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease

CB2 is a potent regulator of immune responses making it a prime target for the treatment of inflammatory diseases.”

http://www.ncbi.nlm.nih.gov/pubmed/21626285